IL128780A0 - An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase - Google Patents

An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase

Info

Publication number
IL128780A0
IL128780A0 IL12878097A IL12878097A IL128780A0 IL 128780 A0 IL128780 A0 IL 128780A0 IL 12878097 A IL12878097 A IL 12878097A IL 12878097 A IL12878097 A IL 12878097A IL 128780 A0 IL128780 A0 IL 128780A0
Authority
IL
Israel
Prior art keywords
polymerase
production
associated viruses
recombinant adeno
viruses utilizing
Prior art date
Application number
IL12878097A
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL128780A0 publication Critical patent/IL128780A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
IL12878097A 1996-09-06 1997-09-04 An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase IL128780A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2469996P 1996-09-06 1996-09-06
PCT/US1997/015716 WO1998010088A1 (en) 1996-09-06 1997-09-04 An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase

Publications (1)

Publication Number Publication Date
IL128780A0 true IL128780A0 (en) 2000-01-31

Family

ID=21821933

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12878097A IL128780A0 (en) 1996-09-06 1997-09-04 An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase

Country Status (6)

Country Link
EP (1) EP0931158A1 (en)
JP (1) JP2001500015A (en)
AU (1) AU722624B2 (en)
CA (1) CA2264482A1 (en)
IL (1) IL128780A0 (en)
WO (1) WO1998010088A1 (en)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU5819599A (en) 1998-09-11 2000-04-03 Regents Of The University Of California, The Recombinant adenovirus for tissue specific expression in heart
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (en) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for helperless production of recombinant adeno-associated virus
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
ES2258601T3 (en) 2001-11-13 2006-09-01 The Trustees Of The University Of Pennsylvania A METHOD FOR THE IDENTIFICATION OF THE UNKNOWN SEQUENCES OF ADENO-ASSOCIATED VIRUSES (VAA) AND A KIT FOR THE METHOD.
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP2573170B1 (en) 2001-12-17 2017-12-20 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor
EP3517134B1 (en) 2001-12-17 2024-01-17 The Trustees of the University of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor
CN100593544C (en) 2002-03-15 2010-03-10 惠氏控股有限公司 Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
EP1648931B1 (en) 2003-07-21 2011-02-09 Transgene S.A. Multifunctional cytokines
US20070073264A1 (en) 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
CN1856576B (en) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
WO2006039218A2 (en) 2004-09-30 2006-04-13 The Trustees Of The University Of Pennsylvania Perfusion circuit and use therein in targeted delivery of macromolecules
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
EP3705579A1 (en) 2006-07-27 2020-09-09 Wyeth LLC High-cell density fed-batch fermentation process for producing recombinant protein
PL2220241T3 (en) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
JP5809978B2 (en) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Simian adenovirus SAdV-43, -45, -46, -47, -48, -49 and -50 and their uses
CN102439157B (en) 2009-04-30 2015-09-16 宾夕法尼亚大学托管会 Comprise the target conducting airways cell composition of adeno associated virus construct
CA2762203A1 (en) 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
WO2011053998A2 (en) * 2009-11-02 2011-05-05 The Salk Institute For Biological Studies Targeting of modifying enzymes for protein evolution
WO2011133890A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Cns targeting aav vectors and methods of use thereof
CN103154257A (en) 2010-09-26 2013-06-12 大玉企业有限公司 Method of recombinant macromolecular production
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
BR112013014457A8 (en) 2010-12-09 2017-12-19 Pasteur Institut uses of the enzyme 6-methylguanine-dna-methyltrasferase (mgmt, ec 2.1.1.63) to increase heterologous protein production, as well as expression vector, recombinant cells and fusion polypeptide comprising peptide secretion signal and snap protein
EP2675902B1 (en) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
ES2931180T3 (en) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Highly inducible dual promoter lentiviral Tet-on type system
WO2013043720A1 (en) 2011-09-20 2013-03-28 The University Of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
JP6348064B2 (en) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア Viral vectors for efficient transgene delivery
MX349562B (en) 2011-12-09 2017-08-02 Pasteur Institut Multiplex immuno screening assay.
HUE054087T2 (en) 2012-04-18 2021-09-28 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
MX358019B (en) 2012-05-18 2018-08-02 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof.
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
US10968446B2 (en) 2012-11-01 2021-04-06 Massachusetts Institute Of Technology Directed evolution of synthetic gene cluster
US9523084B2 (en) 2012-11-08 2016-12-20 Centre National De La Recherche Scientifique (Cnrs) Phosphodeoxyribosyl transferase mutant enzymes and uses thereof
SG10201707319UA (en) 2013-03-15 2017-10-30 Univ Pennsylvania Compositions and methods for treating mpsi
RU2705249C2 (en) 2013-07-12 2019-11-06 Дзе Чилдрен'З Хоспитал Оф Филадельфия Aav vector and neutralizing antibodies against aav (adeno-associated virus) analysis
PT3024498T (en) 2013-07-22 2020-03-06 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
KR102390075B1 (en) 2014-03-09 2022-04-26 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
EP3137497B1 (en) 2014-05-02 2021-04-07 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
JP6895374B2 (en) 2014-07-16 2021-06-30 トランジェーヌＴｒａｎｓｇｅｎｅ Oncolytic virus for expression of immune checkpoint modulator
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
CN107073051B (en) 2014-10-21 2021-08-24 马萨诸塞大学 Recombinant AAV variants and uses thereof
JP6401871B2 (en) 2014-11-05 2018-10-10 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． AADC polynucleotide for the treatment of Parkinson's disease
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CN107427666B (en) 2015-01-30 2022-11-04 加利福尼亚大学校董 Subpial gene delivery system for spinal cord
CN116019934A (en) 2015-02-10 2023-04-28 建新公司 Enhanced delivery of viral particles to striatum and cortex
JP2018506304A (en) 2015-02-10 2018-03-08 ジェンザイム・コーポレーション Variant RNAi
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
IL282053B2 (en) 2015-03-10 2023-03-01 Univ Columbia Recombinant glut1 adeno-associated viral vector constructs , compositions and kits comprising the same and use thereof
TWI707951B (en) 2015-04-08 2020-10-21 美商健臻公司 Production of oversized adeno-associated vectors
CA3019315A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
PT3298134T (en) 2015-05-16 2023-08-18 Genzyme Corp Gene editing of deep intronic mutations
CA2990193A1 (en) 2015-06-23 2016-12-29 The Children's Hospital Of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
KR102197507B1 (en) 2015-07-13 2020-12-31 피벗 바이오, 인크. Methods and compositions for improving plant traits
CA3001001A1 (en) 2015-10-05 2017-04-13 Massachusetts Institute Of Technology Nitrogen fixation using refactored nif clusters
WO2017070525A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Methods and compositions for treating metabolic imbalance in neurodegenerative disease
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US10385320B2 (en) 2015-12-02 2019-08-20 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
WO2017136500A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
EP4094780A3 (en) 2016-02-12 2023-02-08 University of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
WO2017143100A1 (en) 2016-02-16 2017-08-24 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
US10894811B2 (en) 2016-02-22 2021-01-19 The University Of North Carolina At Chapel Hill Peptide inhibitors of calcium channels
KR102336362B1 (en) 2016-03-03 2021-12-08 보이저 테라퓨틱스, 인크. Closed-ended linear duplex DNA for non-viral gene delivery
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
GB201608046D0 (en) 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
EP3458588A4 (en) 2016-05-18 2020-01-15 Voyager Therapeutics, Inc. Modulatory polynucleotides
US20210108225A1 (en) 2016-06-16 2021-04-15 Charite - Universitatsmedizin Berlin Neuropeptide-expressing vectors and methods for the treatment of epilepsy
MA45493A (en) 2016-06-27 2019-05-01 Aicuris Anti Infective Cures Gmbh HCMC ENTRY INHIBITORS.
EP3481433A4 (en) 2016-07-05 2020-02-26 University of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
US11141434B2 (en) 2016-07-07 2021-10-12 Iovance Biotherapeutics, Inc. Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
PE20190401A1 (en) 2016-07-26 2019-03-13 Biomarin Pharm Inc NOVEL CAPSID PROTEINS FROM THE ADENO-ASSOCIATED VIRUS
MX2019001938A (en) 2016-08-15 2019-07-04 Genzyme Corp Methods for detecting aav.
US20190185864A1 (en) 2016-08-23 2019-06-20 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
TW201825674A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing bispecific engager molecules
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
JP7110203B2 (en) 2016-12-28 2022-08-01 トランジェーヌ Oncolytic viruses and therapeutic molecules
CA3049258A1 (en) 2017-01-12 2018-07-19 Pivot Bio, Inc. Methods and compositions for improving plant traits
CA3059112A1 (en) 2017-04-05 2018-10-11 University Of Massachusetts Cep290 minigene therapy
WO2018204694A1 (en) 2017-05-03 2018-11-08 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
JP2020518258A (en) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Amyotrophic lateral sclerosis (ALS) treatment composition and method
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
US20200123203A1 (en) 2017-06-13 2020-04-23 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
US11773407B2 (en) 2017-06-26 2023-10-03 Arizona Board Of Regents On Behalf Of Arizona State University CRISPR logic circuits for safer and controllable gene therapies
KR20200053468A (en) 2017-07-06 2020-05-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Gene therapy to treat type I mucopolysaccharides
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa Oncolytic viruses expressing agents targeting metabolic immune modulators
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CA3076191A1 (en) 2017-09-22 2019-03-28 Genzyme Corporation Variant rnai
AU2018352236A1 (en) 2017-10-16 2020-04-23 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
KR20200135433A (en) 2018-03-23 2020-12-02 유니버시티 오브 매사추세츠 Gene therapy for the treatment of bone disorders
WO2019191701A1 (en) 2018-03-30 2019-10-03 The Board Of Trustees Of Leland Stanford Junior University Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
EP3784290A4 (en) 2018-04-27 2022-03-23 University of Massachusetts Aav capsids identified by in vivo library selection
JP2021521852A (en) 2018-04-27 2021-08-30 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． How to measure the potency of AADC viral vector
SG11202009914SA (en) 2018-05-08 2020-11-27 Rutgers The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
JP2021522811A (en) 2018-05-09 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド How to treat phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
TW202015742A (en) 2018-05-15 2020-05-01 美商航海家醫療公司 Compositions and methods for delivery of aav
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
CN112638936A (en) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 Adenovirus polynucleotides and polypeptides
EP3807404A1 (en) 2018-06-13 2021-04-21 Voyager Therapeutics, Inc. Engineered 5' untranslated regions (5' utr) for aav production
JP2021529513A (en) 2018-07-02 2021-11-04 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Treatment of amyotrophic lateral sclerosis and spinal cord-related disorders
EP3826719A1 (en) 2018-07-24 2021-06-02 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
MX2021001395A (en) 2018-08-03 2021-08-11 Genzyme Corp Variant rnai against alpha-synuclein.
WO2020072683A1 (en) 2018-10-02 2020-04-09 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
TW202035689A (en) 2018-10-04 2020-10-01 美商航海家醫療公司 Methods for measuring the titer and potency of viral vector particles
SG11202103425YA (en) 2018-10-05 2021-05-28 Voyager Therapeutics Inc Engineered nucleic acid constructs encoding aav production proteins
WO2020077165A1 (en) 2018-10-12 2020-04-16 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2020081490A1 (en) 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
AU2019366983A1 (en) 2018-10-25 2021-05-13 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
CA3119302A1 (en) 2018-11-08 2020-05-14 Arizona Board Of Regents On Behalf Of Arizona State University Synthetic immunomodulation with a crispr super-repressor in vivo
US20220033824A1 (en) 2018-11-29 2022-02-03 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
US20220064671A1 (en) 2019-01-18 2022-03-03 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
EP3927380A1 (en) 2019-02-22 2021-12-29 University of Massachusetts Oxr1 gene therapy
US20200299637A1 (en) 2019-03-19 2020-09-24 Massachusetts Institute Of Technology Control of nitrogen fixation in rhizobia that associate with cereals
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
TW202104592A (en) 2019-05-14 2021-02-01 美商拜奧馬林製藥公司 Methods of redosing gene therapy vectors
EP4007814A1 (en) 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
EP4010465A1 (en) 2019-08-09 2022-06-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20220333133A1 (en) 2019-09-03 2022-10-20 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
KR20220079857A (en) 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 AAV-compatible laminin-linker polymeric protein
CN114729333A (en) 2019-09-27 2022-07-08 生物马林药物股份有限公司 Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering techniques
US20210261625A1 (en) 2020-01-29 2021-08-26 Genzyme Corporation Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
MX2022012279A (en) 2020-03-31 2023-02-23 Univ Massachusetts Aav capsids variants and uses thereof.
US20230131352A1 (en) 2020-04-01 2023-04-27 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
TW202144579A (en) 2020-04-09 2021-12-01 美商４Ｍｖａｃ有限責任公司 Use of viral vectors for coronavirus vaccine production
BR112022020753A2 (en) 2020-04-15 2022-12-20 Voyager Therapeutics Inc TAU-BINDING COMPOUNDS
GB202005732D0 (en) 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
CA3182970A1 (en) 2020-05-13 2021-11-18 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
CA3183171A1 (en) 2020-05-13 2021-11-18 Akouos, Inc. Compositions and methods for treating slc26a4-associated hearing loss
AR122079A1 (en) 2020-05-13 2022-08-10 Akouos Inc COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
AU2021309007A1 (en) 2020-07-13 2023-02-16 Transgene Treatment of immune depression
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
JP2023537070A (en) 2020-08-07 2023-08-30 アミカス セラピューティックス インコーポレイテッド Proteins targeting vesicles and uses thereof
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
IL302128A (en) 2020-11-02 2023-06-01 Biomarin Pharm Inc Process for enriching adeno-associated virus
WO2022119839A1 (en) 2020-12-01 2022-06-09 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
WO2022140560A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering Innovations V, Inc. In vitro assembly of anellovirus capsids enclosing rna
WO2022146839A1 (en) 2020-12-29 2022-07-07 Akouos, Inc. Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
TW202241479A (en) 2020-12-30 2022-11-01 美商安迅生物製藥公司 Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202246516A (en) 2021-03-03 2022-12-01 美商航海家醫療公司 Controlled expression of viral proteins
WO2022214632A1 (en) 2021-04-07 2022-10-13 Neoplants Sas Compositions and methods for indoor air remediation
AU2022270611A1 (en) 2021-05-03 2023-10-12 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034994A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034997A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3233097A1 (en) 2021-09-30 2023-04-06 Katherine Diane GRIBBLE Compositions and methods for treating kcnq4-associated hearing loss
CA3235632A1 (en) 2021-11-02 2023-05-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023091948A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2023107188A1 (en) 2021-12-10 2023-06-15 Massachusetts Institute Of Technology Prediction, biosynthesis, and integration as biosensors of molecules with unique light absorbance signatures and their subsequent in-field remote detection using multi or hyper-spectral cameras
WO2023111580A1 (en) 2021-12-16 2023-06-22 University Of Dundee Targeted degradation of alpha-synuclein
WO2023147374A2 (en) 2022-01-25 2023-08-03 Voyager Therapeutics, Inc. Baculovirus expression system
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
WO2023154693A1 (en) 2022-02-08 2023-08-17 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
GB202201713D0 (en) 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
WO2023196862A1 (en) 2022-04-06 2023-10-12 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
WO2023200843A1 (en) 2022-04-12 2023-10-19 The Broad Institute, Inc. Compositions and methods for screening cis regulatory elements
US20230407255A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Dendritic cell assay for innate immunogenicity to gene therapy agents
WO2023201272A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of irak4 modulators for gene therapy
WO2023201274A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of an irak4 modulator for gene therapy
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023220729A2 (en) 2022-05-13 2023-11-16 Flagship Pioneering Innovations Vii, Llc Double stranded dna compositions and related methods
WO2023235791A1 (en) 2022-06-02 2023-12-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024006741A1 (en) 2022-06-28 2024-01-04 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024011112A1 (en) 2022-07-06 2024-01-11 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024009280A1 (en) 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
EP4345106A1 (en) 2022-09-30 2024-04-03 Charité - Universitätsmedizin Berlin Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy
WO2024069010A1 (en) 2022-09-30 2024-04-04 Charité - Universitätsmedizin Berlin Gene therapy vectors for the expression of preprodynorphin variants for the treatment of epilepsy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135855A (en) * 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5591601A (en) * 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
AU688428B2 (en) * 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
PT728214E (en) * 1993-11-09 2004-11-30 Ohio Med College CELL LINES ARE ABLE TO EXPRESS THE ADDITIONAL-ASSOCIATED VIRUS REPLICATION GENE
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
WO1996012010A1 (en) * 1994-10-13 1996-04-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Preparation of rep-negative aav mutants and cells which can be used therefor
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996017947A1 (en) * 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2735789B1 (en) * 1995-06-23 1997-07-25 Centre Nat Rech Scient RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
CA2264482A1 (en) 1998-03-12
AU4183397A (en) 1998-03-26
WO1998010088A1 (en) 1998-03-12
EP0931158A1 (en) 1999-07-28
JP2001500015A (en) 2001-01-09
AU722624B2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
IL128780A0 (en) An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
IL128736A0 (en) Methods using cre-lox for production of recombinant adeno-associated viruses
IL135813A (en) Method for the preparation of citalopram
NO986202D0 (en) Method of Preparation of Recombinant Adunovirus
AU9386198A (en) Inducible methods for repressing gene function
EP0953374A4 (en) Method for purifying effluent gases
GB2315252B (en) Traveling carrier system and method of controlling the same
HUP0103325A2 (en) Method for chromatographically purifying insulins
BR9706661A (en) Process of loading an operating system
EG21056A (en) Method for refining molten silicon
EP1058282A4 (en) Switch, click for switches, and method of fixing click for switches
BR9706239A (en) Process for the preparation of 3- (1-hydroxyphenyl-1-alkoxyimino-methyl) dioxazins
GB9715223D0 (en) Method of manufacturing ceramic member
HK1017380A1 (en) Method of purifying thrombin-like protease enzymesobtained from snake venom.
AU2502899A (en) Method for the elimination of pathogens from solutions containing proteins
DE69728146D1 (en) METHOD AND SYSTEM FOR CONTROLLED OVERHEAD SWITCHING
HUP0000770A2 (en) Process for the purification of substituted p-nitro-diphenyl-ethers
DE69836971D1 (en) METHOD AND APPARATUS FOR PREDICTING FUNCTIONAL PROTEINDOMAINS, METHOD FOR IMPROVING THE PROTEIN FUNCTION, AND FUNCTIONALLY IMPROVED PROTEIN
GB9827156D0 (en) Method of providing quick steering changes
AU6442998A (en) Method for the purification of virus
HUP0003490A3 (en) Method for purifying phthalides
HRP980039B1 (en) Method of purifying 1,3,5-triisopropylbenzene
AU3338597A (en) Method of purifying epsilon-caprolactam
IL131418A0 (en) Method for assembly of multiple dna fragments
ZA978395B (en) Improved method for the determination of lipase